Form 8-K - Current report:
SEC Accession No. 0001641172-25-025104
Filing Date
2025-08-21
Accepted
2025-08-21 17:00:42
Documents
14
Period of Report
2025-08-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 45490
2 EX-10.1 ex10-1.htm EX-10.1 30165
  Complete submission text file 0001641172-25-025104.txt   290822

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE aktx-20250815.xsd EX-101.SCH 3810
4 XBRL DEFINITION FILE aktx-20250815_def.xml EX-101.DEF 26684
5 XBRL LABEL FILE aktx-20250815_lab.xml EX-101.LAB 36827
6 XBRL PRESENTATION FILE aktx-20250815_pre.xml EX-101.PRE 25308
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5374
Mailing Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210
Business Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210 (646) 350-0702
Akari Therapeutics Plc (Filer) CIK: 0001541157 (see all company filings)

EIN.: 981034922 | State of Incorp.: X0
Type: 8-K | Act: 34 | File No.: 001-36288 | Film No.: 251241500
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)